
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Toxicology [M. W., P. W., E. E.] and Medicine [S. H., A. G., W. S.], University of Wuerzburg, D-97078 Wuerzburg, Germany
The effect of enzyme-resistant starch (RS) on the development of colon cancer was reported to include both chemopreventive activity in humans and tumorigenic activity in animals. A study was performed to detect the influence of enzyme-RS on lipid peroxidation-induced DNA damage and cell proliferation. During two 4-week periods, 12 volunteers consumed a controlled diet in which starchy foods were enriched with a highly resistant amylomaize starch (Hylon VII) in the high-RS period and with an available corn starch in the low-RS period (second period). At the end of each test period, biopsy specimens of the rectosigmoidal mucosa were obtained from each subject and analyzed for trans-4-hydroxy-2-nonenal-1,N2-propanodeoxyguanosine-3'-monophosphate adducts using a 32P postlabeling assay, and cell proliferation was determined by bromodeoxyuridine labeling. The trans-4-hydroxy-2-nonenal-1,N2-propanodeoxyguanosine-3'-monophosphate adduct level of DNA from colonic mucosa of eight evaluated volunteers was significantly higher in the high-RS period (mean adducts/107 nucleotides ± SD, 3.83 ± 0.60) than in the low-RS period (2.69 ± 0.35; P < 0.05). There was no evidence for an increased cell proliferation in the upper crypt in the high-RS phase, compared with the low-RS phase. There are indications now that enzyme-RS induces oxidative stress that is not correlated with increased cell proliferation. If it is accepted that the formation of DNA adducts reflects oxidative stress, which in turn accelerates the process of carcinogenesis, then certain forms of RS may have a tumor-enhancing effect rather than a tumor-protective effect.
This article has been cited by other articles:
![]() |
S S Dronamraju, J M Coxhead, S B Kelly, J Burn, and J C Mathers Cell kinetics and gene expression changes in colorectal cancer patients given resistant starch: a randomised controlled trial Gut, March 1, 2009; 58(3): 413 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Arlt, E. Frei, and H. H. Schmeiser ECNIS-sponsored workshop on biomarkers of exposure and cancer risk: DNA damage and DNA adduct detection and 6th GUM-32P-postlabelling workshop, German Cancer Research Center, Heidelberg, Germany, 29-30 September 2006 Mutagenesis, January 1, 2007; 22(1): 83 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G Muir, E. G. Yeow, J. Keogh, C. Pizzey, A. R Bird, K. Sharpe, K. O'Dea, and F. A Macrae Combining wheat bran with resistant starch has more beneficial effects on fecal indexes than does wheat bran alone Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1020 - 1028. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |